• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid progression of a growth hormone producing tumour during dopamine agonist treatment.

作者信息

Heidvall K, Hulting A L

出版信息

Br Med J (Clin Res Ed). 1987 Feb 28;294(6571):546-7. doi: 10.1136/bmj.294.6571.546.

DOI:10.1136/bmj.294.6571.546
PMID:3103768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1245581/
Abstract
摘要

相似文献

1
Rapid progression of a growth hormone producing tumour during dopamine agonist treatment.多巴胺激动剂治疗期间生长激素分泌肿瘤的快速进展
Br Med J (Clin Res Ed). 1987 Feb 28;294(6571):546-7. doi: 10.1136/bmj.294.6571.546.
2
Bromocriptine therapy: Review of mechanism of action, safety and tolerability.溴隐亭治疗：作用机制、安全性和耐受性综述。
Clin Exp Pharmacol Physiol. 2022 Aug;49(8):903-922. doi: 10.1111/1440-1681.13678. Epub 2022 Jun 22.
3
Development of acromegaly during treatment of hyperprolactinemia with bromocriptine: an unusual acidophil stem cell adenoma.溴隐亭治疗高泌乳素血症期间发生肢端肥大症：一例罕见的嗜酸性干细胞腺瘤
J Clin Endocrinol Metab. 1996 Dec;81(12):4484-7. doi: 10.1210/jcem.81.12.8954064.
4
Space occupying growth of a pituitary adenoma producing hGH and hPrl during bromocriptin therapy.在溴隐亭治疗期间，产生生长激素（hGH）和催乳素（hPrl）的垂体腺瘤出现占位性生长。
Clin Neurol Neurosurg. 1977;80(4):251-7. doi: 10.1016/s0303-8467(78)80015-8.
5
A growth-hormone--producing pituitary adenoma and an internal carotid artery aneurysm.
Surg Neurol. 1982 Aug;18(2):108-11. doi: 10.1016/0090-3019(82)90366-4.
6
Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes catch-up growth in a prepubertal child.溴隐亭治疗泌乳素瘤可恢复生长激素分泌，并使青春期前儿童实现追赶生长。
Eur J Pediatr. 2004 Aug;163(8):472-4. doi: 10.1007/s00431-004-1454-5. Epub 2004 May 25.
7
Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995--bromocriptine combined treatment results.与生长激素-催乳素垂体腺瘤相关的非典型McCune-Albright综合征：自然病程、长期随访及SMS 201-995与溴隐亭联合治疗结果
J Clin Endocrinol Metab. 1992 Oct;75(4):1166-9. doi: 10.1210/jcem.75.4.1400888.
8
Association of androgen-producing ovarian tumour and acromegaly.
Acta Clin Belg. 1992;47(6):429-30. doi: 10.1080/17843286.1992.11718266.
9
Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.一名患有多骨纤维发育不良患者的肢端肥大症和高催乳素血症：动态内分泌研究及生长抑素类似物奥曲肽治疗
J Endocrinol Invest. 1994 Jan;17(1):59-65. doi: 10.1007/BF03344964.
10
Medical and surgical management of functional pituitary tumors.
Clin Neurosurg. 1981;28:374-83. doi: 10.1093/neurosurgery/28.cn_suppl_1.374.

引用本文的文献

1
Significance of recombinant human growth hormone therapy in promoting growth and development of children with idiopathic short stature.重组人生长激素治疗对特发性矮小儿童生长发育的意义
Pak J Med Sci. 2022 Sep-Oct;38(7):2016-2020. doi: 10.12669/pjms.38.7.6535.
2
Acromegaly. Recognition and treatment.肢端肥大症。识别与治疗。
Drugs. 1994 Mar;47(3):425-45. doi: 10.2165/00003495-199447030-00004.

本文引用的文献

1
Bomocriptine treatment of patients with acromegaly resistant to conventional therapy.
Clin Endocrinol (Oxf). 1980 Mar;12(3):219-24. doi: 10.1111/j.1365-2265.1980.tb02703.x.
2
The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly.血浆催乳素水平在预测肢端肥大症患者生长激素分泌对溴隐亭和促甲状腺激素释放激素反应性中的价值。
Eur J Clin Invest. 1982 Apr;12(2):151-5. doi: 10.1111/j.1365-2362.1982.tb00952.x.
3
Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats.
Endocrinology. 1984 Oct;115(4):1269-74. doi: 10.1210/endo-115-4-1269.
4
Long-term treatment of acromegaly with bromocriptine.用溴隐亭长期治疗肢端肥大症。
Br Med J. 1977 Apr 2;1(6065):875-8. doi: 10.1136/bmj.1.6065.875.